Related Experiment Videos
Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved
Colin A Graham1, Brian P McIlhatton, Claire W Kirk
1Regional Genetics Centre, Belfast City Hospital, Belfast BT9 7AB, Northern Ireland, UK. colin.graham@bll.n-i.nhs.uk
Atherosclerosis
|September 15, 2005
Summary
Improved genetic screening for familial hypercholesterolemia (FH) significantly increases mutation detection rates. This enhanced testing identifies more genetic causes of high cholesterol, aiding clinical diagnosis and management of FH.
Area of Science:
- Genetics
- Cardiovascular Disease
- Molecular Biology
Background:
- Familial hypercholesterolemia (FH) is a prevalent single-gene disorder linked to coronary artery disease.
- Previous genetic screening of the low-density lipoprotein receptor (LDLR) gene and Apolipoprotein B (ApoB) R3500Q mutation identified defects in only ~20% of definite FH patients.
Purpose of the Study:
- To enhance the genetic screening protocol for Familial hypercholesterolemia (FH) by including non-coding intron splice regions.
- To determine the diagnostic yield of the improved screening in patients with definite and possible FH.
- To investigate the role of the NARC-1 gene in FH etiology.
Main Methods:
- Expanded genetic screening to include intron splice regions of the LDLR gene.
- Sequenced the NARC-1 gene in patients with unidentified LDLR or ApoB mutations.
- Analyzed mutation expression at the RNA level for identified splice site mutations.
Main Results:
- The improved screening protocol increased mutation detection to 87% in definite FH patients (n=68).
- A 26% detection rate was achieved in possible FH patients (n=130) using a limited screen.
- Splice site mutations accounted for 14% of LDLR defects, with one mutation (c.1845+11 c>g) confirmed at the RNA level.
- No NARC-1 mutations were found, suggesting a minor role in FH.
Conclusions:
- Enhanced genetic screening, including splice regions, significantly improves FH mutation detection rates.
- The improved test is valuable for clinical screening programs and diagnosis of FH.
- While most genetic causes are now identifiable, a small percentage of FH cases remain genetically unexplained, indicating the need for further gene discovery.